Abstract: The present disclosure provides a nano-structural protein degradation tool, use, and a preparation method thereof, wherein the nano-structural protein degradation tool comprises: one of or a combination of several of a first degradation tool, a second degradation tool, and a third degradation tool, wherein the first degradation tool is formed by linking POI recognition groups to linkers; the second degradation tool is formed by linking the POI recognition groups to nanoparticles; and the third degradation tool is formed by linking the POI recognition groups to the nanoparticles through the linkers. The present disclosure further provides a lipid-based protein degradation tool, use, and a preparation method thereof, wherein the lipid-based protein degradation tool comprises: POI recognition groups, and lipid hybrid substances linked to the POI recognition groups.

Abstract: The present disclosure provides an siRNA nanocapsule and a preparation method and use thereof, relating to the technical field of biomedical engineering. The siRNA nanocapsule provided in the present disclosure includes siRNA and a shell encapsulating the siRNA and polymerized by a monomer A and a monomer B. The monomer A has a double bond at one end, and is electrostatically bound with the siRNA, and the monomer B includes molecules for improving tumor microenvironment sensitivity. The siRNA nanocapsule provided in the present disclosure is suitable for a wide range of clinical applications.

Abstract: The disclosure relates to a two-dimensional (2D) bismuth nanocomposite, and a preparation method and use thereof, and belongs to the field of nanobiotechnology. The 2D bismuth nanocomposite of the disclosure is an ultra-thin bismuth nanosheet that is loaded with platinum nanoparticles and modified with indocyanine green (ICG) and surface targeting polypeptide Ang-2. The 2D bismuth nanocomposite Bi@Pt/ICG-Ang2 of the disclosure can not only realize the targeted photothermal and photodynamic combination therapy for tumors, but also realize the dual-mode imaging combining CT and fluorescence imaging.

Abstract: The disclosure provides a hybrid membrane camouflaged nanomedicine loaded with oxidative phosphorylation inhibitor and preparation method thereof. The nanomedicine comprises an inner core and an outer shell coated on the periphery of the inner core. The inner core is a ROS-responsive drug-loaded nanoparticle, and the drug loaded by the ROS-responsive nanocarrier is an oxidative phosphorylation inhibitor. The outer shell is a hybrid membrane of mitochondrial membrane and cancer cell membrane. The nanomedicines can cross the BBB and reach tumor sites by the homologous targeting of cancer cell membrane, and then they can homologously target and enter mitochondria by the mitochondrial membrane. Subsequently, under the high-level ROS environment of the mitochondria, the ROS responsive drug-loaded nanoparticle releases the oxidative phosphorylation inhibitor due to the swell and degradation of the inner core, so that the safe and efficient targeted GBM therapy is achieved.

Abstract: The present disclosure provides a gene editing nanocapsule and a preparation method and use thereof. The gene editing nanocapsule has a core-shell structure, wherein the inner core includes a Cas/sgRNA ribonucleoprotein complex, and the outer shell includes a polymer, the Cas/sgRNA ribonucleoprotein complex has a gene editing function, and the polymer acts as a carrier for the Cas/sgRNA ribonucleoprotein complex and protects it, because the polymer contains tumor microenvironment sensitive molecules, the nanocapsules can be efficiently released in tumor cells. Further, the surface of the outer shell can be modified with a targeting agent, so that the nanocapsule can specifically target tumor cells, which improves the endocytosis efficiency of the nanocapsule. The gene editing nanocapsule has good biocompatibility and biosafety, and is expected to become a safe and efficient gene therapy drug for tumors.

Abstract: The present disclosure provides an siRNA nanocapsule and a preparation method and use thereof, relating to the technical field of biomedical engineering. The siRNA nanocapsule provided in the present disclosure includes siRNA and a shell encapsulating the siRNA and polymerized by a monomer A and a monomer B. The monomer A has a double bond at one end, and is electrostatically bound with the siRNA, and the monomer B includes molecules for improving tumor microenvironment sensitivity. The siRNA nanocapsule provided in the present disclosure is suitable for a wide range of clinical applications.

Abstract: The present disclosure discloses preparation and use of sugar-targeting nanoparticles for modifying siRNA. A sugar-targeting nanoparticle, including targeting nanocarriers, wherein the targeting nanocarriers are formed by linking in sequence a targeting molecule, a first linking compound, a first hydrophilic biomaterial, a second linking compound and a cationic compound through chemical bonds; the first linking compound and the second linking compound both have a carboxyl group; the first linking compound has a maleimido group at the same time, and the targeting molecule is a cycloaldohexose.

Abstract: The present disclosure provides a drug carrier, a brain-targeting nanodrug based on CRISPR gene editing technology and a preparation method and use thereof. The nanodrug contains nanoparticles prepared by coupling Cas9/sgRNA and drug carriers. The drug carrier includes a polymer mPEG-P (GPMA, FPMA) and a polymer Ang-PEG-PGPMA, wherein a structural formula of the mPEG-P (GPMA, FPMA) is: a structural formula of the polymer Ang-PEG-PGPMA is: where n is 35-45, x1 is 15-20, y is 2-4, m is 75-85, and x2=x1. The guanidino group of the drug carrier can be combined with the ribonucleoprotein complex by electrostatic action, salt bridge formation, or hydrogen bonding action. Also provided are methods of suppressing and treating tumors at a gene level using the drug carrier to transport the therapeutic drug to the lesion site.

Abstract: The disclosure relates to a two-dimensional (2D) bismuth nanocomposite, and a preparation method and use thereof, and belongs to the field of nanobiotechnology. The 2D bismuth nanocomposite of the disclosure is an ultra-thin bismuth nanosheet that is loaded with platinum nanoparticles and modified with indocyanine green (ICG) and surface targeting polypeptide Ang-2. The 2D bismuth nanocomposite Bi@Pt/ICG-Ang2 of the disclosure can not only realize the targeted photothermal and photodynamic combination therapy for tumors, but also realize the dual-mode imaging combining CT and fluorescence imaging.